Newman PA, Lee SJ, Duan N, Rudy E, Nakazono TK, Boscardin J, Kakinami L, Shoptaw S, Diamant A, Cunningham WE. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).
Health Serv Res 2009;
44:2167-79. [PMID:
19780857 DOI:
10.1111/j.1475-6773.2009.01039.x]
[Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
OBJECTIVE
To assess HIV vaccine acceptability among high-risk adults in Los Angeles.
STUDY SETTING
Sexually transmitted disease clinics, needle/syringe exchange programs, Latino community health/HIV prevention programs.
STUDY DESIGN
Cross-sectional survey using conjoint analysis. Participants were randomly selected using three-stage probability sampling.
DATA COLLECTION
Sixty-minute structured interviews. Participants rated acceptability of eight hypothetical vaccines, each with seven dichotomous attributes, and reported post-vaccination risk behavior intentions.
PRINCIPAL FINDINGS
Participants (n=1164; 55.7 percent male, 82.4 percent ethnic minority, mean age=37.4 years) rated HIV vaccine acceptability from 28.4 to 88.6; mean=54.5 (SD=18.8; 100-point scale). Efficacy had the greatest impact on acceptability, followed by side effects and out-of-pocket cost. Ten percent would decrease condom use after vaccination.
CONCLUSIONS
Findings support development of social marketing interventions to increase acceptability of "partial efficacy" vaccines, behavioral interventions to mitigate risk compensation, and targeted cost subsidies.
Collapse